鼻胃插管患者质子泵抑制剂的使用与吸入性肺炎发病的相关性  

Correlation between proton pump inhibitor use and incidence of aspiration pneumonia in patients with nasogastric intubation

作　　者：唐蜜蜜[1] 董李晨 杨中保[1] 胡毅翔 张小琴[1] TANG Mi-mi;DONG Li-chen;YANG Zhong-bao;HU Yi-xiang;ZHANG Xiao-qin(Department of Pharmacy,the Fourth Hospital of Changsha,Changsha 410000,China;Department of Pharmacy,Xiangtan Central Hospital,Xiangtan 411000,China)

机构地区：[1]湖南省长沙市第四医院药学部,长沙市410000 [2]湖南省湘潭市中心医院药学部,湘潭市411000

出　　处：《广西医学》2021年第19期2318-2321,共4页Guangxi Medical Journal

基　　金：湖南省长沙市卫生健康委员会科研项目(CSWJ201807);湖南省卫生健康委员会科研项目(20201046)。

摘　　要：目的探讨鼻胃插管患者质子泵抑制剂(PPI)的使用与吸入性肺炎(AP)发病的相关性。方法将70例鼻胃插管患者随机分为对照组和实验组,每组35例。在常规治疗基础上,对照组不采用PPI类药物治疗,实验组采用PPI类药物治疗,均连续治疗14 d。观察两组患者AP的发生率,检测两组患者血清胃泌素-17水平,分析鼻胃插管患者发生AP的影响因素。结果治疗后,实验组的AP发生率为42.86%(15/35),对照组为5.71%(2/35),实验组AP发生率和血清胃泌素-17表达水平均高于对照组(均P<0.05)。口服用PPI类药物是导致鼻胃插管患者并发AP的危险因素(P<0.05)。结论PPI的口服是导致鼻胃插管患者发生AP的危险因素。Objective To investigate the correlation between proton pump inhibitor(PPI)use and the incidence of aspiration pneumonia(AP)in patients with nasogastric intubation.Methods Seventy patients with nasogastric intubation were randomly divided into control group and experimental group,with 35 cases in each group.On the basis of conventional treatment,the control group did not receive PPI therapy,the experimental group received PPI therapy,and both groups were treated for 14 consecutive days.The incidence rate of AP was observed in the two groups,serum gastrin-17 level was detected in the two groups,and the influencing factors for developing AP were analyzed in patients with nasogastric intubation.Results After treatment,the incidence rate of AP was 42.86%(15/35)in the experimental group and 5.71%(2/35)in the control group,the experimental group yielded a higher incidence rate of AP and a higher expression level of serum gastrin-17 than the control group(all P<0.05).Oral administration of PPI drugs was a risk factor resulting in concomitant AP in patients with nasogastric intubation(P<0.05).Conclusion Oral administration of PPI is a risk factor resulting in AP in patients with nasogastric intubation.

关 键 词：质子泵抑制剂 鼻胃插管 吸入性肺炎 胃泌素-17 

分 类 号：R563.1[医药卫生—呼吸系统]